• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Solesence Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    6/2/25 6:00:36 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $SLSN alert in real time by email
    false 0000883107 0000883107 2025-05-27 2025-05-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K
    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 27, 2025

     

    SOLESENCE, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 001-42589 36-3687863
    (State or other (Commission (IRS Employer
    jurisdiction of File Number) Identification No.)
    incorporation)    

     

    1319 Marquette Drive

    Romeoville, Illinois 60446

    (Address of Principal Executive Offices) (Zip Code)

     

    (630) 771-6708

    (Registrant’s telephone number, including area code)

      

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.01 par value per share SLSN The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On May 27, 2025, Solésence, Inc. (the “Company”) entered into a (i) Third Amendment to Business Loan Agreement (the “Term Loan Agreement Amendment”) with Strandler, LLC, an affiliate of our controlling shareholder, Bradford T. Whitmore, (ii) Third Amendment to Amended and Restated Business Loan Agreement (the “A/R Loan Agreement Amendment”) with Beachcorp, LLC, which is also an affiliate of our controlling shareholder, Bradford T. Whitmore (“Beachcorp”), and (iii) Third Amendment to Business Loan Agreement with Beachcorp (the “Revolving Loan Agreement Amendment” and together with the Term Loan Agreement Amendment and the A/R Term Loan Agreement Amendment, the “Loan Agreement Amendments”). The Revolving Loan Agreement Amendment increased the maximum borrowing capacity thereunder from $5.2 million to $10.0 million. The A/R Loan Agreement Amendment increased the maximum borrowing capacity thereunder from $8.0 million to $12.0 million. In addition, the Loan Agreement Amendments extended the maturity date under each respective loan agreement from to October 1, 2025 to April 30, 2027. The Company entered into the Loan Agreement Amendments for working capital and other general corporate purposes.

     

    The description of the terms and conditions of the Loan Agreement Amendments does not purport to be complete and is qualified in its entirety by the full text of the Loan Agreement Amendments, which are filed as exhibits to this Current Report on Form 8-K.

     

    Item 7.01 Regulation FD Disclosure.

     

    On June 2, 2025, the Company issued a press release. A copy of that press release is furnished as Exhibit 99.1 and incorporated herein by reference.

     

    The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Term Loan Agreement Amendment, dated May 27, 2025.
         
    10.2   A/R Loan Agreement Amendment, dated May 27, 2025.
         
    10.3   Revolving Loan Agreement Amendment, dated May 27, 2025.
         
    99.1   Press Release, dated June 2, 2025.
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: June 2, 2025

     

      NANOPHASE TECHNOLOGIES CORPORATION
         
      By: /s/ JESS JANKOWSKI
        Name: Jess Jankowski
        Title: Chief Executive Officer

     

     

     

    Get the next $SLSN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLSN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SLSN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Whitmore Bradford T bought $28,093,800 worth of shares (6,689,000 units at $4.20) and sold $28,093,800 worth of shares (6,689,000 units at $4.20) (SEC Form 4)

      4 - SOLESENCE, INC. (0000883107) (Issuer)

      6/2/25 4:01:15 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary

    $SLSN
    Financials

    Live finance-specific insights

    See more
    • Solésence Reports Record First Quarter 2025 Financial Results

      First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025.    Recent Highlights and Accomplishments Uplisted to Nasdaq under the ticker "SLSN" supporting the Company's increased visibility with the investment communityAchieved record revenue and unit volume shipments in the first quarter 2025 "We kicked off 2025 with record revenue, fueled by strong sales across our suite of consumer products," said Jess Jankowski, President and

      5/5/25 4:01:00 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary
    • Solésence To Report First Quarter 2025 Financial Results and Host a Conference Call

      ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2025 after the market close on Monday, May 5, 2025, and host a conference call and webcast on the same date. First Quarter 2025 Conference Call Details Date / Time: Monday, May 5, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/q53hzimg Dial-In Link: https://register-conf.

      4/28/25 4:01:00 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary

    $SLSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Cureton Kevin exercised 43,500 shares at a strike of $0.42 and sold $166,051 worth of shares (43,500 units at $3.82) (SEC Form 4)

      4 - SOLESENCE, INC. (0000883107) (Issuer)

      6/6/25 7:00:04 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary
    • Large owner Whitmore Bradford T bought $28,093,800 worth of shares (6,689,000 units at $4.20) and sold $28,093,800 worth of shares (6,689,000 units at $4.20) (SEC Form 4)

      4 - SOLESENCE, INC. (0000883107) (Issuer)

      6/2/25 4:01:15 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary

    $SLSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solésence Expands Debt Facilities to Fuel Growth Initiatives

      ROMEOVILLE, Ill., June 02, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its existing loan agreements, providing increased borrowing capacity to support the execution of strategic objectives. The new facility expands the Company's three loan agreements to a maximum borrowing capacity from $14.2 million to $23.0 million and extends the maturity date under each respective loan agreement from October 1, 2025 to April 30, 2027. The additional borrowing capacity provides Solésence with significant financial flexibil

      6/2/25 8:00:00 AM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary
    • Solésence Reports Record First Quarter 2025 Financial Results

      First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025.    Recent Highlights and Accomplishments Uplisted to Nasdaq under the ticker "SLSN" supporting the Company's increased visibility with the investment communityAchieved record revenue and unit volume shipments in the first quarter 2025 "We kicked off 2025 with record revenue, fueled by strong sales across our suite of consumer products," said Jess Jankowski, President and

      5/5/25 4:01:00 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary
    • Solésence To Report First Quarter 2025 Financial Results and Host a Conference Call

      ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2025 after the market close on Monday, May 5, 2025, and host a conference call and webcast on the same date. First Quarter 2025 Conference Call Details Date / Time: Monday, May 5, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/q53hzimg Dial-In Link: https://register-conf.

      4/28/25 4:01:00 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary

    $SLSN
    SEC Filings

    See more
    • Solesence Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SOLESENCE, INC. (0000883107) (Filer)

      6/2/25 6:00:36 AM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form 10-Q filed by Solesence Inc.

      10-Q - SOLESENCE, INC. (0000883107) (Filer)

      5/13/25 5:29:50 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary
    • Solesence Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SOLESENCE, INC. (0000883107) (Filer)

      5/7/25 4:20:12 PM ET
      $SLSN
      Package Goods/Cosmetics
      Consumer Discretionary